Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch
onand Analysis of Financial Condition and Results of Operations in Iomai'sQuarterly Report on Form 10-Q for the three months ended September 302007 and filed with the Securities and Exchange Commission. Whether anyapproved product would be self-administered would depend on many factorsincluding the outcome of any additional studies the Company conductsevaluating self-administration and th
on
and Analysis of Financial Condition and Results of Operations in Iomai's
Quarterly Report on Form 10-Q for the three months ended September 30,
2007, and filed with the Securities and Exchange Commission. Whether any
approved product would be self-administered would depend on many factors,
including the outcome of any additional studies the Company conducts
evaluating self-administration and the views of regulatory agencies. Iomai
cautions investors and others not to place undue reliance on the forward-
looking statements contained in this press release. Iomai's business is
subject to many risks. For a discussion of such risks, you are encouraged
to read the documents the Company files with the U.S. Securities and
Exchange Commission, available at http://www.sec.gov. The statements in
this press release speak only as of the date of this document, and Iomai
undertakes no obligation to update or revise the statements.
'/>"/>